Parsonex Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$287K Buy
+549
New +$281K 0.21% 48
2026
Q2
– Sell
-499
Closed -$223K – 59
2026
Q1
$223K Sell
499
-532
-52% -$248K 0.22% 52
2025
Q4
$467K Buy
1,031
+13
+1% +$5.6K 0.3% 57
2025
Q3
$399K Buy
1,018
+218
+27% +$91.1K 0.27% 61
2025
Q2
$356K Buy
+800
New +$369K 0.3% 66

Other funds holding VRTX

Parsonex Advisory Services's VRTX Position: Q3 2026 in Review

Parsonex Advisory Services opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 549 shares worth $287K. The stake represents 0.21% of the portfolio and ranks #48 among its holdings. This is a return to the name: Parsonex Advisory Services previously reported a position in VRTX as recently as Q1 2026.

Parsonex Advisory Services first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $467K in Q4 2025. 1,793 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Parsonex Advisory Services held 549 shares of Vertex Pharmaceuticals worth $287K as of Q3 2026.
  • Vertex Pharmaceuticals was a new Parsonex Advisory Services position in Q3 2026.
  • Vertex Pharmaceuticals made up 0.21% of Parsonex Advisory Services's portfolio in Q3 2026, its #48 holding.
  • Parsonex Advisory Services first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Parsonex Advisory Services's Vertex Pharmaceuticals position peaked at $467K in Q4 2025.
  • 1,793 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Parsonex Advisory Services's 13F filing for Q3 2026, filed 13 Nov 2026.